Cited by 486Liver Disease Diagnosis and TreatmentInflammasome and immune disordersLiver physiology and pathology

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

NLRP3 inflammasome activation is required for fibrosis development in NAFLD

Open access

Wree, Alexander, McGeough, Matthew D., Peña, Carla A., Schlattjan, Martin, Li, Hongying, Inzaugarat, Maria Eugenia, Messer, Karen, Canbay, Ali, Hoffman, Hal M., Feldstein, Ariel E.·2014·Journal of Molecular Medicine

DOI 10.1007/s00109-014-1170-1PMC PMC4349416

Open this paper in CoChat — free account Open PDF

Abstract

NLR inflammasomes, caspase 1 activation platforms critical for processing key pro-inflammatory cytokines, have been implicated in the development of nonalcoholic fatty liver disease (NAFLD). As the direct role of the NLRP3 inflammasome remains unclear, we tested effects of persistent NLRP3 activation as a contributor to NAFLD development and, in particular, as a modulator of progression from benign hepatic steatosis to steatohepatitis during diet-induced NAFLD. Gain of function tamoxifen-inducible Nlrp3 knock-in mice allowing for in vivo temporal control of NLRP3 activation and loss of function Nlrp3 knockout mice were placed on short-term choline-deficient amino acid-defined (CDAA) diet, to induce isolated hepatic steatosis or long-term CDAA exposure, to induce severe steatohepatitis and fibrosis, respectively. Expression of NLRP3 associated proteins was assessed in liver biopsies of a well-characterized group of patients with the full spectrum of NAFLD. Nlrp3(-/-) mice were protected from long-term feeding CDAA-induced hepatomegaly, liver injury, and infiltration of activated macrophages. More importantly, Nlrp3(-/-) mice showed marked protection from CDAA-induced liver fibrosis. After 4 weeks on CDAA diet, wild-type (WT) animals showed isolated hepatic steatosis while Nlrp3 knock-in mice showed severe liver inflammation, with increased infiltration of activated macrophages and early signs of liver fibrosis. In the liver samples of patients with NAFLD, inflammasome components were significantly increased in those patients with nonalcoholic steatohepatitis (NASH) when compared to those with non-NASH NAFLD with mRNA levels of pro-IL1 beta correlated to levels of COL1A1. Our study uncovers a crucial role for the NLRP3 inflammasome in the development of NAFLD. These findings may lead to novel therapeutic strategies aimed at halting the progression of hepatic steatosis to the more severe forms of this disease. Key message: Mice with NLRP3 inflammasome loss of function are protected from diet-induced steatohepatitis. NLRP3 inflammasome gain of function leads to early and severe onset of diet-induced steatohepatitis in mice. Patients with severe NAFLD exhibit increased levels of NLRP3 inflammasome components and levels of pro-IL1β mRNA correlate with the expression of COL1A1.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00109-014-1170-1

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
The Inflammasome
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Self-citation
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Self-citation
Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T.-H., Brickey, W. J., & Ting, J. P.-Y. (2011) · Nature Immunology · doi:10.1038/ni.2022 · Cited by 1,698

Show all 43 references

Sorted by citations

Items 201–300 of 485

Deoxycholic Acid Promotes Pyroptosis in Free Fatty Acid-Induced Steatotic Hepatocytes by Inhibiting PINK1-Mediated Mitophagy
Gao, X., Ruan, Y., Zhu, X., Lin, X., Yan, X., Li, X., Mai, M., & Guo, H. (2021) · Inflammation · doi:10.1007/s10753-021-01573-1 · Cited by 37
NAFLD: An Emerging Causal Factor for Cardiovascular Disease
Li, M., Wang, H., Zhang, X., Cai, J., & Li, H. (2023) · Physiology · doi:10.1152/physiol.00013.2023 · Cited by 41
Self-citation
Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma
Henderson, J. M., Polak, N., Chen, J., Roediger, B., Weninger, W., Kench, J. G., McCaughan, G. W., Zhang, H. E., & Gorrell, M. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-28486-8 · Cited by 36
Gut–Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology
Maroni, L., Ninfole, E., Pinto, C., Benedetti, A., & Marzioni, M. (2020) · Cells · doi:10.3390/cells9030736 · Cited by 37
NLRP3 inflammasome in digestive diseases: From mechanism to therapy
Qiang, R., Li, Y., Dai, X.-C., & Lv, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978190 · Cited by 39
Lipid droplet efferocytosis attenuates proinflammatory signaling in macrophages via TREM2- and MS4A7-dependent mechanisms
Zhou, L., Lu, Y., Qiu, X., Chen, Z., Tang, Y., Meng, Z., Yan, C., Du, H., Li, S., & Lin, J. D. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115310 · Cited by 41
Hepatitis regulation by the inflammasome signaling pathway
Negash, A. A., & Gale, M. (2015) · Immunological Reviews · doi:10.1111/imr.12279 · Cited by 37
Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High‐Fat Diet: Possible Role of the NLRP3 Inflammasome
Fantauzzi, C. B., Menini, S., Iacobini, C., Rossi, C., Santini, E., Solini, A., & Pugliese, G. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8962458 · Cited by 36
The P2X7 Receptor and NLRP3 Axis in Non-Alcoholic Fatty Liver Disease: A Brief Review
Rossato, M., Vincenzo, A. D., Pagano, C., Hadi, H. E., & Vettor, R. (2020) · Cells · doi:10.3390/cells9041047 · Cited by 36
Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3
Xia, Y., Wang, P., Yan, N., Gonzalez, F. J., & Yan, T. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03243-w · Cited by 38
The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products
Shao, G., Liu, Y., Lu, L., Zhang, G., Zhou, W., Wu, T., Wang, L., Xu, H., & Ji, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944088 · Cited by 37
Pro‐inflammatory signalling and gut‐liver axis in non‐alcoholic and alcoholic steatohepatitis: Differences and similarities along the path
Glaser, T., Baiocchi, L., Zhou, T., Francis, H., Lenci, I., Grassi, G. B., Kennedy, L. L., Liangpunsakul, S., Glaser, S. S., Alpini, G. D., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15182 · Cited by 35
Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome
Kim, H., Choi, Y. J., Kim, S. K., Kim, H., Jun, D. W., Yoon, K., Kim, N., Hwang, J., Kim, Y. M., Lim, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02345-1 · Cited by 35
Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation
Zhang, X., Gao, R., Zhou, Z., Sun, J., Tang, X., Li, J., Zhou, X., & Shen, T. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115405 · Cited by 35
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Petagine, L., Zariwala, M. G., & Patel, V. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i32.4831 · Cited by 39
Gut microbiota–NLRP3 inflammasome crosstalk in metabolic dysfunction-associated steatotic liver disease
Yu, T., Luo, L., Xue, J., Tang, W., Wu, X., & Fan, Y. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102458 · Cited by 41
Role of dietary fatty acids in liver injury caused by vinyl chloride metabolites in mice
Anders, L. C., Yeo, H., Kaelin, B. R., Lang, A. L., Bushau-Sprinkle, A. M., Douglas, A. N., Cave, M. C., Arteel, G. E., McClain, C. J., & Beier, J. I. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.026 · Cited by 34
Estrogen Receptor α Regulates Metabolic-Associated Fatty Liver Disease by Targeting NLRP3–GSDMD Axis-Mediated Hepatocyte Pyroptosis
Gao, X., Liu, S., Tan, L., Ding, C., Fan, W., Gao, Z., Li, M., Tang, Z., Wu, Y., Xu, L., et al. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05400 · Cited by 34
CREBH alleviates mitochondrial oxidative stress through SIRT3 mediating deacetylation of MnSOD and suppression of Nlrp3 inflammasome in NASH
Zhang, J., Zhao, Y., Wang, S., Li, G., & Xu, K. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.07.018 · Cited by 33
Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob/ob mice
Meng, L., Zheng, J.-Y., Qiu, Y.-H., Li, Z., Zheng, J.-Y., Liu, Y., Miao, X.-L., & Lu, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109099 · Cited by 33
Immunoregulation by lipids during the development of non-alcoholic steatohepatitis.
Ramadori, P., Kroy, D. C., & Streetz, K. L. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2015.01.02 · Cited by 31
Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease
Pan, M., Zheng, C., Deng, Y., Tang, K., Nie, H., Xie, J., Liu, D., Tu, G.-F., Yang, Q.-H., & Zhang, Y. (2021) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2021.07.004 · Cited by 32
Hepatic nucleotide binding oligomerization domain‐like receptors pyrin domain‐containing 3 inflammasomes are associated with the histologic severity of non‐alcoholic fatty liver disease
Mitsuyoshi, H., Yasui, K., Hara, T., Taketani, H., Ishiba, H., Okajima, A., Seko, Y., Umemura, A., Nishikawa, T., Yamaguchi, K., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12883 · Cited by 32
Therapeutic modulation of the liver immune microenvironment
Tilg, H., Adolph, T. E., & Tacke, F. (2023) · Hepatology · doi:10.1097/hep.0000000000000386 · Cited by 32
Insights into the evolving role of the gut microbiome in nonalcoholic fatty liver disease: rationale and prospects for therapeutic intervention
Mouzaki, M., & Loomba, R. S. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819858470 · Cited by 31
Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis
Fang, Q., Li, X., Wang, M., Qiao, X., Huang, F., Hu, C., Xue, Y., Zhao, S., & Lin, Y. (2022) · Food & Function · doi:10.1039/d2fo00012a · Cited by 31
ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study
Cyr, B. S., Keane, R. W., & Vaccari, J. P. D. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228580 · Cited by 31
Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target
Çolak, Y., Hasan, B., ŞENATEŞ, B. E., Tandon, K. S., Zervos, X. B., Menzo, E. L., & Erim, T. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101710 · Cited by 28
Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis?
Handa, P., Vemulakonda, L. A., Kowdley, K. V., Uribe, M., & Méndez‐Sánchez, N. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i31.6965 · Cited by 30
The diverse roles of macrophages in metabolic inflammation and its resolution
Ray, A. G., Odum, O., Wiseman, D., & Weinstock, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147434 · Cited by 31
Isoquercitrin Attenuates Steatohepatitis by Inhibition of the Activated NLRP3 Inflammasome through HSP90
Ma, J., Li, M., Yang, T., Deng, Y., Ding, Y., Guo, T., & Shang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108795 · Cited by 31
Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization
Jiang, K., Lu, S., Li, D., Liu, M., Hu, J., Lei, B., Wang, S., Long, K., He, S., & Zhong, F. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02002-w · Cited by 29
Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis
Qin, W., & Weng, J. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.06.003 · Cited by 29
The Absence of NLRP3-inflammasome Modulates Hepatic Fibrosis Progression, Lipid Metabolism, and Inflammation in KO NLRP3 Mice during Aging
Gallego, P., Castejón‐Vega, B., Campo, J. A. D., & Cordero, M. D. (2020) · Cells · doi:10.3390/cells9102148 · Cited by 29
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Zhang, E., Zhao, Y., & Hu, H. (2021) · Hepatology Communications · doi:10.1002/hep4.1611 · Cited by 30
Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy‐proven non‐alcoholic fatty liver disease
Lang, S., Martin, A., Zhang, X., Farowski, F., Wisplinghoff, H., Vehreschild, M. J. G. T., Krawczyk, M. J., Nowag, A., Kretzschmar, A., Scholz, C. J., et al. (2021) · Liver International · doi:10.1111/liv.14899 · Cited by 29
Linking nutrient sensing, mitochondrial function, and PRR immune cell signaling in liver disease
Kemper, C., & Sack, M. N. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.09.002 · Cited by 27
Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study
Liu, Z., Wang, Q., Huang, H., Wang, X., & Xu, C. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00997-z · Cited by 29
Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease
Zarzour, R. A., Alshawsh, M. A., Asif, M., Al‐Mansoub, M. A., Mohamed, Z., Ahmad, M., Majid, A. M. S. A., Asmawi, M. Z., Kaur, G., Al-dualimi, D. W., et al. (2018) · Nutrients · doi:10.3390/nu10081057 · Cited by 28
Early microcystin-LR exposure-linked inflammasome activation in mice causes development of fatty liver disease and insulin resistance
Albadrani, M. S., Saha, P., Mondal, A., Seth, R. K., Sarkar, S., Kimono, D. A., Bose, D., Porter, D. E., Scott, G., Brooks, B. W., et al. (2020) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2020.103457 · Cited by 28
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
Welch, R. D., Billon, C., Losby, M., Bedia‐Diaz, G., Fang, Y., Avdagic, A., Elgendy, B., Burris, T. P., & Griffett, K. (2022) · Metabolites · doi:10.3390/metabo12030238 · Cited by 28
JT002, a small molecule inhibitor of the NLRP3 inflammasome for the treatment of autoinflammatory disorders
Ambrus-Aikelin, G., Takeda, K., Joetham, A., Lazic, M., Povero, D., Santini, A. M., Pranadinata, R., Johnson, C. D., McGeough, M. D., Beasley, F. C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39805-z · Cited by 28
Self-citation
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 30
Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice
Li, Y., Sun, J.-P., Wang, J., Lu, W., Xie, L., Lv, J., Li, H., & Yang, S. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.06.045 · Cited by 28
Self-citation
Oxymatrine alleviates high-fat diet/streptozotocin-induced non-alcoholic fatty liver disease in C57BL/6 J mice by modulating oxidative stress, inflammation and fibrosis
Lou, D., Fang, Q., He, Y., Ma, R., Wang, X., Li, H., & Qi, M.-Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116491 · Cited by 31
Self-citation
MyD88 in Macrophages Enhances Liver Fibrosis by Activation of NLRP3 Inflammasome in HSCs
Ge, S., Yang, W. P., Chen, H., Yuan, Q., Liu, S., Zhao, Y., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212413 · Cited by 29
Nod-like receptor protein 3 inflammasome activation by Escherichia coli RNA induces transforming growth factor beta 1 secretion in hepatic stellate cells
Wang, H., Liu, S., Wang, Y., Chang, B., & Wang, B. (2016) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2016.699 · Cited by 27
Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice
de Sant’Ana, L. P., Ribeiro, D. J. S., Martins, A. M. A., dos Santos, F. N., Corrêa, R., Almeida, R. D. N., Eberlin, M. N., Maurice, C. F., & Magalhães, K. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02926 · Cited by 26
A Sweet Connection? Fructose’s Role in Hepatocellular Carcinoma
Dewdney, B., Roberts, A. A., Qiao, L., George, J., & Hebbard, L. (2020) · Biomolecules · doi:10.3390/biom10040496 · Cited by 29
Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review
Brennan, P., Clare, K., Casella, G., & Dillon, J. F. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i15.1683 · Cited by 26
Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice
Zou, J., Yan, C., & Wan, J. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00573-z · Cited by 26
The Role of the Stress Response in Metabolic Dysfunction-Associated Fatty Liver Disease: A Psychoneuroendocrineimmunology-Based Perspective
Demori, I., & Grasselli, E. (2023) · Nutrients · doi:10.3390/nu15030795 · Cited by 30
NOD-like Receptors—Emerging Links to Obesity and Associated Morbidities
Bauer, S., Hezinger, L., Rexhepi, F., Ramanathan, S., & Kufer, T. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108595 · Cited by 26
Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
Pezzino, S., Luca, T., Castorina, M., Puleo, S., Latteri, S., & Castorina, S. (2024) · Life · doi:10.3390/life14010093 · Cited by 27
Connexins and pannexins in liver damage
Yanguas, S. C., Willebrords, J., Maes, M., da Silva, T. C., Pereira, I. V. A., Cogliati, B., Dagli, M. L., & Vinken, M. (2016) · EXCLI journal · doi:10.17179/excli2016-119 · Cited by 26
Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review
Chen, Y., Wu, W., & Wu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175999 · Cited by 29
Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis
Zhu, S., Liao, L., Zhong, Y., Liu, Z., Lu, J., Yang, Z., Xiao, Y., & Xu, X. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.008 · Cited by 28
Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease
Chen, S., Guo, H., Xie, M., Zhou, C., & Zheng, M. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107609 · Cited by 25
The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis
Torres, S., Brol, M. J., Magdaleno, F., Schierwagen, R., Uschner, F. E., Klein, S., Ortiz, C., Tyc, O., Bachtler, N., Stunden, J., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.715765 · Cited by 25
Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
Sharma, S. P., Suk, K. T., & Kim, D. J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i37.6161 · Cited by 28
Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
Novi, S., Vestuto, V., Campiglia, P., Tecce, N., Bertamino, A., & Tecce, M. F. (2023) · Nutrients · doi:10.3390/nu15122748 · Cited by 26
Unveiling the flames: macrophage pyroptosis and its crucial role in liver diseases
Ni, L., Chen, D., Zhao, Y., Ye, R., & Fang, P. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1338125 · Cited by 24
PI3K inhibition reduces murine and human liver fibrogenesis in precision-cut liver slices
Gore, E., Bigaeva, E., Oldenburger, A., Kim, Y. O., Rippmann, J. F., Schuppan, D., Boersema, M., & Olinga, P. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113633 · Cited by 25
BRP39 Regulates Neutrophil Recruitment in NLRP3 Inflammasome-Induced Liver Inflammation
Kui, L., Kim, A. D., Onyuru, J., Hoffman, H. M., & Feldstein, A. E. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.12.002 · Cited by 24
Self-citation
Compound C Protects Mice from HFD-Induced Obesity and Nonalcoholic Fatty Liver Disease
Wang, F., Liu, Y., Yuan, J., Yang, W., & Mo, Z. (2019) · International Journal of Endocrinology · doi:10.1155/2019/3206587 · Cited by 24
Corrigendum: Alveolar Dynamics and Beyond – the Importance of Surfactant Protein C and Cholesterol in Lung Homeostasis and Fibrosis
Sehlmeyer, K., Ruwisch, J., Roldán, N., & López-Rodríguez, E. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00943 · Cited by 24
Polyphenols as NLRP3 inflammasome modulators in cardiometabolic diseases: a review of in vivo studies
Villalva, M., Martínez-García, J. J., Jaime, L., Santoyo, S., Pelegrı́n, P., & Pérez‐Jiménez, J. (2023) · Food & Function · doi:10.1039/d3fo03015f · Cited by 27
Ginger essential oil prevents NASH progression by blocking the NLRP3 inflammasome and remodeling the gut microbiota-LPS-TLR4 pathway in mice
Panyod, S., Wu, W., Hsieh, Y.-C., Tseng, Y.-J., Peng, S.-Y., Chen, R.-A., Huang, H., Chen, Y., Shen, T. D., Ho, C., et al. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00306-1 · Cited by 30
FNDC4 reduces hepatocyte inflammatory cell death via AMPKα in metabolic dysfunction-associated steatotic liver disease
Neira, G., Becerril, S., Valentí, V., Moncada, R., Catalán, V., Gómez‐Ambrosi, J., Colina, I., Silva, C., Escalada, J., Frühbeck, G., et al. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.08.007 · Cited by 25
Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis
Tølbøl, K. S., Stierstorfer, B., Rippmann, J. F., Veidal, S. S., Rigbolt, K. T. G., Schönberger, T., Gillum, M. P., Hansen, H. H., Vrang, N., Jelsing, J., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5395-7 · Cited by 23
Gegen Qinlian Decoction Ameliorates Hyperuricemia-Induced Renal Tubular Injury via Blocking the Inflammatory Signaling Pathway
Wang, X., Qi, Y., Guan, H., Lin, H., He, P., Guan, K., Fu, L., Ye, M., Xiao, J., & Wu, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.665398 · Cited by 23
Epiberberine regulates lipid synthesis through SHP (NR0B2) to improve non-alcoholic steatohepatitis
Zhou, L.-M., Fan, J., Minmin, X., Xiong, M.-Y., Wang, Q.-J., Chai, X., Li, X.-D., Li, X., & Ye, X.-L. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166639 · Cited by 23
Macrophage metabolism in nonalcoholic fatty liver disease
Zhang, W., & Lang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257596 · Cited by 28
Brucella abortus Infection Elicited Hepatic Stellate Cell-Mediated Fibrosis Through Inflammasome-Dependent IL-1β Production
Benítez, P. C. A., Viglietti, A. I. P., Gomes, M. T. R., Oliveira, S. C., Quarleri, J. F., Giambartolomei, G. H., & Delpino, M. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03036 · Cited by 23
Gut–Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers
Gil‐Gómez, A., Brescia, P., Rescigno, M., & Romero‐Gómez, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723752 · Cited by 24
The Impact of Melatonin and NLRP3 Inflammasome on the Expression of microRNAs in Aged Muscle
Sayed, R. K. A., Fernández‐Ortiz, M., Fernández‐Martínez, J., Aranda‐Martínez, P., Guerra‐Librero, A., Rodríguez-Santana, C., de Haro, T., Escames, G., Acuña-Castroviejo, D., & Rusanova, I. (2021) · Antioxidants · doi:10.3390/antiox10040524 · Cited by 25
Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD)
Theys, C., Vanderhaeghen, T., Dijck, E. V., Peleman, C., Scheepers, A., Ibrahim, J., Mateiu, L. M., Timmermans, S., Berghe, T. V., Francque, S., et al. (2024) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2023.1283170 · Cited by 23
Protective effects of maslinic acid on high fat diet-induced liver injury in mice
Li, T., Wang, H., Dong, S., Liang, M., Ma, J., Jiang, X., & Yu, W. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120634 · Cited by 22
The Effector Protein BPE005 from Brucella abortus Induces Collagen Deposition and Matrix Metalloproteinase 9 Downmodulation via Transforming Growth Factor β1 in Hepatic Stellate Cells
Benítez, P. C. A., Serantes, D. R., Herrmann, C. K., Viglietti, A. I. P., Vanzulli, S. I., Giambartolomei, G. H., Comerci, D. J., & Delpino, M. V. (2015) · Infection and Immunity · doi:10.1128/iai.01227-15 · Cited by 22
Pyroptosis and gasdermins—Emerging insights and therapeutic opportunities in metabolic dysfunction-associated steatohepatitis
Stoess, C., Leszczynska, A., Kui, L., & Feldstein, A. E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1218807 · Cited by 24
Self-citation
Immunostimulatory activity and structure-activity relationship of epimedin B from Epimedium brevicornu Maxim.
Gao, Y., Shi, W., Tu, C., Li, P., Zhao, G., Xiao, X., Wang, J., & Bai, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015846 · Cited by 20
Omega-3 pleiad: The multipoint anti-inflammatory strategy
Batista, E. D. S., Nakandakari, S. C. B. R., da Silva, A. S. R., Pauli, J. R., de Moura, L. P., Ropelle, E. R., Camargo, E. A., & Cintra, D. E. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2146044 · Cited by 22
The capsaicinoid nonivamide suppresses the inflammatory response and attenuates the progression of steatosis in a NAFLD‐rat model
Wikan, N., Tocharus, J., Oka, C., Sivasinprasasn, S., Chaichompoo, W., Suksamrarn, A., & Tocharus, C. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23279 · Cited by 21
The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status
Stojić, J., Kukla, M., & Grgurević, I. (2023) · Diagnostics · doi:10.3390/diagnostics13182960 · Cited by 21
Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift
Drori, A., Rotnemer-Golinkin, D., Avni, S., Drori, A., Danay, O., Levanon, D., Tam, J., Zolotarev, L., & Ilan, Y. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0688-4 · Cited by 21
Rapeseed Protein-Derived Antioxidant Peptide RAP Ameliorates Nonalcoholic Steatohepatitis and Related Metabolic Disorders in Mice
Zhao, Q., Xu, H., Hong, S., Song, N., Xie, J., Yan, Z., Wang, R., Yang, P., & Jiang, X. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01030 · Cited by 21
Dehydromevalonolactone ameliorates liver fibrosis and inflammation by repressing activation of NLRP3 inflammasome
Niu, W., Bao, Y., Zhang, N., Lu, Z.-N., Ge, M., Li, Y., Li, Y., Chen, M., & He, H. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105971 · Cited by 19
Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency
Rocco, M. D., Pisciotta, L., Madeo, A., Bertamino, M., & Bertolini, S. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0768-8 · Cited by 20
Plant Sterol Ester of α-Linolenic Acid Attenuates Nonalcoholic Fatty Liver Disease by Rescuing the Adaption to Endoplasmic Reticulum Stress and Enhancing Mitochondrial Biogenesis
Han, H., Guo, Y., Li, X., Shi, D., Xue, T., Wang, L., Li, Y., & Zheng, M. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8294141 · Cited by 21
Dual role of neutrophils in modulating liver injury and fibrosis during development and resolution of diet-induced murine steatohepatitis
Kim, A. D., Kim, S. E., Leszczynska, A., Kaufmann, B., Reca, A., Kim, D. J., & Feldstein, A. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-03679-w · Cited by 19
Self-citation
Plant-derived bioactive compounds regulate the NLRP3 inflammasome to treat NAFLD
Huang, Q., Xin, X., Sun, Q., An, Z., Gou, X., & Feng, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.896899 · Cited by 22
Genetic deletion or pharmacologic inhibition of the Nlrp3 inflammasome did not ameliorate experimental NASH
Ioannou, G. N., Horn, C. L., Kothari, V. M., Yeh, M. M., Shyu, I., Lee, S. P., & Savard, C. E. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100330 · Cited by 20
Myeloid-specific deletion of chitinase-3-like 1 protein ameliorates murine diet-induced steatohepatitis progression
Kim, A. D., Kui, L., Kaufmann, B. K., Kim, S. E., Leszczynska, A., & Feldstein, A. E. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02325-4 · Cited by 30
Self-citation
Mangiferin for the Management of Liver Diseases: A Review
Li, L., Dong, Y., Liu, X., & Wang, M. (2023) · Foods · doi:10.3390/foods12132469 · Cited by 21
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 22
Research Progress of Pyroptosis in Fatty Liver Disease
Li, R., Xue, W., Wei, H., Fan, Q., Li, X., Qiu, Y., & Cui, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713065 · Cited by 20
Ameliorative role of bioactive phytoconstituents targeting obesity associated NAFLD by modulation of inflammation and lipogenesis pathways: a comprehensive review
Barbhuiya, P. A., Sen, S., & Pathak, M. P. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-023-09912-w · Cited by 20
Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease
ALVARES, D. C. L., HOFFMAN, S. S., Stankovic, B., & Adeli, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.12.010 · Cited by 21
Antrodia Cinnamomea Attenuates Non-Alcoholic Steatohepatitis by Suppressing NLRP3 Inflammasome Activation In Vitro and In Vivo
Yen, I., Lin, J., Chen, Y., Tu, Q.-W., & Lee, S. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500937 · Cited by 19
The role of REV-ERB in NASH
Griffett, K., Hayes, M. E., Boeckman, M. P., & Burris, T. P. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00883-w · Cited by 18

Authors: Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E.
Affiliations: University of California San Diego (US)
Essen University Hospital (DE)
Corresponding author: Feldstein, Ariel E.
ORCID: Wree, Alexander
Schlattjan, Martin
Li, Hongying
Messer, Karen
Canbay, Ali
Hoffman, Hal M.
Feldstein, Ariel E.
Venue: Journal of Molecular Medicine
Publisher: Springer Science and Business Media LLC
Published: 2014-05-28
Volume: 92
Issue: 10
Pages: 1069-1082
ISSN: 0946-2716 (ISSN-L)
1432-1440
DOI: 10.1007/s00109-014-1170-1
PMC: PMC4349416
OpenAlex: W1977508200
Cited by: 486
References: 43
Citations by year: 2026: 18 · 2025: 31 · 2024: 31 · 2023: 64 · 2022: 66 · 2021: 63 · 2020: 69 · 2019: 27 · 2018: 37 · 2017: 33 · 2016: 27 · 2015: 17 · 2014: 3
FWCI: 20.20
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Journal of Molecular Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Americanae (AECID Library) (submittedVersion, cc-by-nc-sa)
eScholarship (California Digital Library) (submittedVersion)
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA022489)
National Cancer Institute (P30CA023100)
National Institute of Allergy and Infectious Diseases (AI52430, R01AI052430)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082451, R01DK076852, DK082451, DK-076852)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: NLRP3 inflammasome, non-alcoholic fatty liver disease, liver fibrosis, steatohepatitis, hepatic steatosis, NLRP3 knockout mice, pro-IL-1β, COL1A1, macrophage infiltration, liver inflammation, caspase-1
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Collagen Type I, alpha 1 Chain, Animals, Carrier Proteins, Female, Fibrosis, Humans, Liver, Male, Mice, Transgenic, RNA, Messenger, Collagen Type I, Inflammasomes, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NLRP3 inflammasome activation is required for fibrosis development in NAFLD

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks